Otsuka Beijing Research

Aripiprazole IM Depot (internal code 31-08-248) is an intramuscular depot formulation of aripiprazole, a dopamine D2 receptor antagonist and serotonin 5-HT2a receptor antagonist, developed by Otsuka Beijing Research Institute for the treatment of schizophrenia. The program has completed Phase 3 clinical development, with the most recent milestone recorded on 26 November 2014. Aripiprazole is an established antipsychotic with multiple approved formulations globally, including oral tablets and other depot preparations under the brand name ABILIFY. The IM depot formulation represents a long-acting injectable strategy designed to improve medication adherence in schizophrenia patients requiring maintenance therapy.

Aripiprazole is approved across major regulatory jurisdictions: the United States (multiple ANDA and NDA approvals from numerous manufacturers including Otsuka), the European Union (10 EMA product authorizations), and Australia (multiple PBS-listed formulations). The regulatory status of this specific IM depot formulation in these jurisdictions is not yet disclosed. The program's completion of Phase 3 trials suggests advancement toward regulatory submission, though no filing or approval dates have been disclosed. The competitive landscape includes multiple approved antipsychotics with varying mechanisms and formulations, including other long-acting injectables such as INVEGA and SAPHRIS.

Schizophrenia affects millions globally and requires long-term maintenance antipsychotic therapy. A significant clinical challenge is medication non-adherence, which leads to relapse, hospitalization, and poor functional outcomes. Long-acting injectable (LAI) formulations address this unmet need by providing sustained drug delivery over weeks to months, reducing the burden of daily oral medication and improving treatment outcomes in real-world settings.

The aripiprazole IM depot formulation enters a competitive but clinically important market segment. Aripiprazole itself is one of the most widely prescribed antipsychotics globally, with extensive clinical evidence and favorable tolerability. An IM depot formulation could capture market share from patients currently using oral aripiprazole or other LAI antipsychotics. The commercial significance is substantial given the large schizophrenia patient population and the clinical preference for LAI formulations in maintenance treatment.

Otsuka's development of this formulation leverages the established safety and efficacy profile of aripiprazole while addressing the adherence problem through depot technology. The patient population—individuals with schizophrenia requiring long-term treatment—represents a substantial commercial opportunity. Competitive positioning depends on the formulation's injection frequency, tolerability, and pricing relative to existing LAI options such as INVEGA (paliperidone palmitate) and other approved depot antipsychotics.

Drug Class: Atypical antipsychotic (second-generation antipsychotic)

Mechanism of Action: Dopamine D2 receptor antagonist and serotonin 5-HT2a (5-HT2A) receptor antagonist

Modality: Small molecule

Route of Administration: Intramuscular injection (depot formulation)

Target: D2 dopamine receptor

Therapeutic Class: Nervous system agents (ATC N05)

Brand Name: ABILIFY (aripiprazole)

Related Therapies: Other approved antipsychotics include paliperidone (INVEGA), olanzapine (APO-OLANZAPINE ODT), risperidone (APO-RISPERIDONE), lurasidone (APO-LURASIDONE), and asenapine (SAPHRIS). Aripiprazole is available in multiple formulations: oral tablets, orally disintegrating tablets, oral solution, and other injectable formulations.

First Approval: Aripiprazole oral formulation was first approved in the United States in 2002 (NDA021436). Multiple generic and branded formulations have since been approved across the US, EU, and Australia.

Patent Status: Not yet disclosed in the provided facts.

United States: Aripiprazole is approved via multiple NDAs (NDA021436, NDA021713, NDA021729, NDA021866, NDA202971, NDA207202, NDA211448, NDA216655, NDA217006) and ANDAs from numerous manufacturers including Otsuka, Accord, Mylan, Teva, and others. The regulatory status of this specific IM depot formulation is not yet disclosed.

European Union: Aripiprazole is approved under 10 EMA product authorizations (EMEA/H/C/000471, EMEA/H/C/002755, EMEA/H/C/003803, EMEA/H/C/003899, EMEA/H/C/003926, EMEA/H/C/004008, EMEA/H/C/004021, EMEA/H/C/004236, EMEA/H/C/005062, EMEA/H/C/005929) with multiple marketing authorization holders including Otsuka Pharmaceutical Netherlands B.V., Sandoz, Mylan, Accord, Generics (UK), and Zentiva. Authorization dates range from January 2026 to April 2026. The status of the IM depot formulation in the EU is not yet disclosed.

Australia: Aripiprazole is approved and PBS-listed with multiple codes (10219W, 10224D, 14790K, 14824F, 15122X, 15128F, 8717T, 8718W, 8719X, 8720Y) from sponsors including Alphapharm, Apotex, Arrow Pharma, Generic Health, and Lundbeck Australia. First listed dates include 2004-05-01, 2015-03-01, and 2016-12-01. The IM depot formulation status is not yet disclosed.

China (NMPA): Aripiprazole is in clinical trials in China (NCT03510325). The regulatory status of this IM depot formulation is not yet disclosed.

Japan (PMDA): No regulatory information provided in the available facts.

Strategic Implications: Otsuka's development of an aripiprazole IM depot formulation leverages the company's established position in antipsychotic therapeutics and builds on the extensive clinical validation of aripiprazole. Completion of Phase 3 trials suggests the program is advancing toward regulatory submission, though no filing dates have been disclosed. The timing of the latest milestone (November 2014) indicates this program may have progressed to regulatory review or post-marketing surveillance in certain jurisdictions.

Competitive Implications: The IM depot formulation targets the adherence-critical maintenance treatment segment where LAI antipsychotics have demonstrated clinical and economic value. Success depends on differentiation through injection frequency, duration of action, and tolerability relative to INVEGA (paliperidone palmitate), which dominates the LAI antipsychotic market. Aripiprazole's favorable metabolic profile may appeal to patients and clinicians concerned about weight gain and metabolic adverse effects.

Future Catalysts: Key catalysts include regulatory submissions and approvals in major markets (US, EU, Japan), publication of Phase 3 trial results in peer-reviewed journals, and real-world effectiveness data post-launch. Pricing and reimbursement decisions will significantly impact market penetration. Label expansions to other indications (e.g., bipolar disorder, depression augmentation) could broaden the commercial opportunity.

Expected Milestones: Regulatory filing and approval timelines are not yet disclosed. Market launch timing depends on regulatory decisions in priority markets. Post-launch surveillance and long-term safety data collection will be critical for maintaining market position.